Skip to Content

Synagis (palivizumab) Disease Interactions

There is 1 disease interaction with Synagis (palivizumab):

Major

Palivizumab (Includes Synagis) ↔ platelet disorders

Severe Potential Hazard, High plausibility. Applies to: Coagulation Defect, Thrombocytopathy, Thrombocytopenia

Palivizumab is administered by IM injection and the risk of bleeding is increased in the presence of platelet function disorders and/or thrombocytopenia. Therapy with palivizumab should be administered cautiously in patients with coagulation disorders or thrombocytopenia.

References

  1. "Product Information. Synagis (palivizumab)." Ross Product Division Pharmaceuticals, Columbus, OH.

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide